İçeriğe geç
akaturk Akademik ölçüm
Giriş Kayıt

Akademisyen

SEMA TÜRKER

DOÇENT

BAHÇEŞEHİR ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ

  • Ana Dal Sağlık Bilimleri Temel Alanı
  • Yan Dal Tıbbi Onkoloji (İç Hastalıkları)

Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.

  • Makale 61
  • Proje 0
  • Kitap 0
  • Bildiri 14
  • Patent 0
  • Sanatsal 0
Scopus (SJR) Q1 6 Q2 18 Q3 24 Q4 7
WoS (JCR) Q1 8 Q2 11 Q3 14 Q4 19
TR Index 5 makale

Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.

Üst %1 makale 0
Üst %10 makale 4
Ort. yüzdelik 54.0%
Üst %1 payı 0.0%
Üst %10 payı 6.9%

Makaleler

YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.

Dizin filtreleri

Toplam 61 yayın

Scopus (SJR)
Q1 6 Q2 18 Q3 24 Q4 7
WoS (JCR)
Q1 8 Q2 11 Q3 14 Q4 19
TR Index
5 makale

Makale listesi

  1. 2026 Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study BMC CANCER DOI 10.1186/s12885-026-15725-9 YÖKSİS SJR Q2 JCR Q2 OpenAlex 13.0%
  2. 2026 Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis JOURNAL OF CLINICAL MEDICINE DOI 10.3390/jcm15041657 YÖKSİS SJR Q2 JCR Q1 OpenAlex üst %10 OpenAlex 97.0%
  3. 2026 Real-world outcomes of trastuzumab deruxtecan in patients with HER2+metastatic breast cancer: Turkish oncology group multicenter study THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY DOI 10.1177/17588359261430583 YÖKSİS SJR Q1 JCR Q2 OpenAlex üst %10 OpenAlex 91.3%
  4. 2025 Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study Scientific Reports DOI 10.1038/s41598-025-19899-3 YÖKSİS SJR Q1 JCR Q1 OpenAlex 34.0%
  5. 2025 Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study Current Oncology DOI 10.3390/curroncol32110639 YÖKSİS SJR Q2 JCR Q2 OpenAlex 33.9%
  6. 2025 Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study CURRENT ONCOLOGY DOI 10.3390/curroncol32110639 YÖKSİS JCR Q2 OpenAlex 33.9%
  7. 2025 Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study JOURNAL OF CHEMOTHERAPY DOI 10.1080/1120009X.2024.2366683 YÖKSİS SJR Q3 JCR Q3 OpenAlex 50.8%
  8. 2025 Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study Scientific Reports DOI 10.1038/s41598-025-19899-3 YÖKSİS SJR Q1 JCR Q1 OpenAlex 34.0%
  9. 2024 The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing JOURNAL OF CHEMOTHERAPY DOI 10.1080/1120009X.2024.2305066 YÖKSİS SJR Q3 JCR Q3 OpenAlex 58.4%
  10. 2023 PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study Journal of Geriatric Oncology DOI 10.1016/j.jgo.2023.101604 YÖKSİS SJR Q2 JCR Q2 OpenAlex 88.5%
  11. 2023 Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy BMC CANCER DOI 10.1186/s12885-023-10662-3 YÖKSİS SJR Q2 JCR Q2
  12. 2023 PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study Journal of Geriatric Oncology DOI 10.1016/j.jgo.2023.101604 YÖKSİS SJR Q2 JCR Q2 OpenAlex 88.5%
  13. 2023 Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy BMC CANCER DOI 10.1186/s12885-023-10609-8 YÖKSİS SJR Q2 JCR Q2 OpenAlex üst %10 OpenAlex 94.2%
  14. 2023 Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy BMC CANCER DOI 10.1186/s12885-023-10609-8 YÖKSİS SJR Q2 JCR Q2 OpenAlex üst %10 OpenAlex 94.2%
  15. 2022 Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study CANCER INVESTIGATION DOI 10.1080/07357907.2021.2017952 YÖKSİS SJR Q2 JCR Q4 OpenAlex 58.0%
  16. 2022 Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group Journal of Gastrointestinal Cancer DOI 10.1007/s12029-021-00594-1 YÖKSİS SJR Q3 JCR Q4 OpenAlex 64.0%
  17. 2021 Trastuzumab±Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group Journal of Gastrointestinal Cancer DOI 10.1007/s12029-021-00594-1 YÖKSİS SJR Q3 JCR Q4 OpenAlex 64.0%
  18. 2021 The relation between inflammation-based parameters and survival in metastatic pancreatic cancer Journal of Cancer Research and Therapeutics DOI 10.4103/jcrt.JCRT_773_19 YÖKSİS SJR Q3 JCR Q4 OpenAlex 72.8%
  19. 2021 The impact of lymph node ratio on overall survival in patients with colorectal cancer Journal of Cancer Research and Therapeutics DOI 10.4103/jcrt.JCRT_11_19 YÖKSİS SJR Q3 JCR Q4 OpenAlex 61.9%
  20. 2021 The relation between inflammation-based parameters and survival in metastatic pancreatic cancer JOURNAL OF CANCER RESEARCH AND THERAPEUTICS DOI 10.4103/jcrt.JCRT_773_19 YÖKSİS SJR Q3 JCR Q4 OpenAlex 72.8%

Akademisyenlere dön